Herpes B Medication
- Author: Sowmya Nanjappa, MD; Chief Editor: Pranatharthi Haran Chandrasekar, MBBS, MD more...
Specific antiviral agents are recommended as soon as possible to attempt prevention of herpes B virus disease progression in humans or when prophylaxis is indicated. No treatment is currently approved for herpes B virus infection by the US Food and Drug Administration. Early treatment has been successful in modifying infection in some animal models, but human data, albeit anecdotal, have been mixed. The progression of complications seems to be limited in some human reports. The dosing, especially for prophylaxis, is not clearly delineated. Because of its bioavailability profile, valacyclovir seems preferable to acyclovir for oral use in either treatment or prophylaxis.
Topical antiseptic compounds or preparations are used topically on potentially contaminated or infected body surfaces or on inanimate objects. In these cases, the topical antiseptics are used to inactivate any herpes B virus remaining in the wound after irrigation.
Nucleoside analogs are initially phosphorylated by viral thymidine kinase to eventually form a nucleoside triphosphate. These molecules inhibit HSV polymerase with 30-50 times the potency of human alpha-DNA polymerase. Herpes B virus thymidine kinase has only recently been characterized. Initial in vitro study has suggested that, under experimental conditions, B virus thymidine kinase is less susceptible to several commonly used antiherpes drugs, including acyclovir and ganciclovir. This may lead to further research aimed at developing more effective alternatives than the currently accepted drugs for this infection.
Synthetic purine nucleoside analogue with activity against a number of herpesviruses, including herpes B. Primarily available in preparations for PO and IV use. Highly selective for virus-infected cells because of high affinity for viral thymidine-kinase enzyme. This effect serves to concentrate acyclovir monophosphate into virus-infected cells. The monophosphate is then metabolized into triphosphate active form by cellular kinases.
Hydrochloride salt of the L-valyl ester of acyclovir. Rapidly converted into acyclovir after prompt absorption from the gut via first-pass intestinal or hepatic metabolism. An alternative to acyclovir for prophylaxis (or possibly treatment).
These agents are to be used for decontamination of affected areas. Scrubbing should persist for at least 15 min.
Broad-spectrum germicidal agent used topically on skin or mucous membranes. Used as a surgical scrub or topical cleanser. Elemental iodine is the active form.
Effective, safe, and reliable topical wash or PO mouthwash antiseptic. A polybiguanide with bactericidal activity; usually is supplied as a gluconate salt. At physiologic pH, the salt dissociates to a cation that binds to bacterial cell walls. Commercially available central venous catheters impregnated with chlorhexidine and silver sulfadiazine are available.
Originally described by Dakin in 1915. Made from sodium carbonate, salt, bleaching powder, and boric acid. Today, commonly referred to 0.5% sodium hypochlorite (a 1:10 dilution of household bleach). Solution deteriorates with time and should be made fresh. Further dilutions also can be made. Some physicians use it as part of pressure ulcer management. Because of potential injury, other topical antiseptics usually are used.
Fan Q, Amen M, Harden M, Severini A, Griffiths A, Longnecker R. Herpes B virus utilizes human nectin-1 but not HVEM or PILRa for cell-cell fusion and virus entry. J Virol. 2012 Apr. 86(8):4468-76. [Medline]. [Full Text].
Du T, Zhou G, Roizman B. Modulation of reactivation of latent herpes simplex virus 1 in ganglionic organ cultures by p300/CBP and STAT3. Proc Natl Acad Sci U S A. 2013 Jul 9. 110(28):E2621-8. [Medline]. [Full Text].
Fujima, A, Ochiai Y, Saito A, et al. Discrimination of Antibody to Herpes B Virus from Antibody to Herpes Simplex Virus Types 1 and 2 in Human and Macaque Sera. J Clin Microbiol. Jan 2008. 46(1):56-61. [Medline]. [Full Text].
Oya C, Ochiai Y, Taniuchi Y, Takano T, Ueda F, Yoshikawa Y, et al. Specific detection and identification of herpes B virus by a PCR-microplate hybridization assay. J Clin Microbiol. 2004 May. 42(5):1869-74. [Medline].
Focher F, Lossani A, Verri A, et al. Sensitivity of Monkey B Virus (Cercopithecine herpesvirus 1) to Antiviral Drugs: Role of Thymidine Kinase in Antiviral Activities of Substrate Analogs and Acyclonucleosides. Antimicrob. Agents Chemother. Jun 2007. 51(6):2028-2024. [Medline]. [Full Text].
Bennett AM, Slomka MJ, Brown DW, et al. Protection against herpes B virus infection in rabbits with a recombinant vaccinia virus expressing glycoprotein D. J Med Virol. 1999 Jan. 57(1):47-56. [Medline].
Bryan BL, Espana CD, Emmons RW, et al. Recovery from encephalomyelitis caused by Herpesvirus simiae. Report of a case. Arch Intern Med. 1975 Jun. 135(6):868-70. [Medline].
Chellman GJ, Lukas VS, Eugui EM, et al. Activation of B virus (Herpesvirus simiae) in chronically immunosuppressed cynomolgus monkeys. Lab Anim Sci. 1992 Apr. 42(2):146-51. [Medline].
Davenport DS, Johnson DR, Holmes GP, et al. Diagnosis and management of human B virus (Herpesvirus simiae) infections in Michigan. Clin Infect Dis. 1994 Jul. 19(1):33-41. [Medline].
Fierer J, Bazely P, Braude AI. Herpes B virus encephalomyelitis presenting as ophthalmic zoster. A possible latent infection reactivated. Ann Intern Med. 1973 Aug. 79(2):225-8. [Medline].
Freifeld AG, Hilliard J, Southers J, et al. A controlled seroprevalence survey of primate handlers for evidence of asymptomatic herpes B virus infection. J Infect Dis. 1995 Apr. 171(4):1031-4. [Medline].
Hilliard JK, Weigler BJ. The existence of differing monkey B virus genotypes with possible implications for degree of virulence in humans. Lab Anim Sci. 1999 Feb. 49(1):10-1. [Medline].
Holmes GP, Chapman LE, Stewart JA, et al. Guidelines for the prevention and treatment of B-virus infections in exposed persons. The B virus Working Group. Clin Infect Dis. 1995 Feb. 20(2):421-39. [Medline].
Holmes GP, Hilliard JK, Klontz KC, et al. B virus (Herpesvirus simiae) infection in humans: epidemiologic investigation of a cluster. Ann Intern Med. 1990 Jun 1. 112(11):833-9. [Medline].
Jainkittivong A, Langlais RP. Herpes B virus infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Apr. 85(4):399-403. [Medline].
Kessler MJ, Hilliard JK. Seroprevalence of B virus (Herpesvirus simiae) antibodies in a naturally formed group of rhesus macaques. J Med Primatol. 1990. 19(2):155-60. [Medline].
Ostrowski SR, Leslie MJ, Parrott T, Abelt S, Piercy PE. B-virus from pet macaque monkeys: an emerging threat in the United States?. Emerg Infect Dis. 1998 Jan-Mar. 4(1):117-21. [Medline].
Palmer AE. B virus, Herpesvirus simiae: historical perspective. J Med Primatol. 1987. 16(2):99-130. [Medline].
Perelygina L, Patrusheva I, Hombaiah S, Zurkuhlen H, Wildes MJ, Patrushev N, et al. Production of herpes B virus recombinant glycoproteins and evaluation of their diagnostic potential. J Clin Microbiol. 2005 Feb. 43(2):620-8. [Medline].
Scinicariello F, Eberle R, Hilliard JK. Rapid detection of B virus (herpesvirus simiae) DNA by polymerase chain reaction. J Infect Dis. 1993 Sep. 168(3):747-50. [Medline].
Weigler BJ. Biology of B virus in macaque and human hosts: a review. Clin Infect Dis. 1992 Feb. 14(2):555-67. [Medline].
Weigler BJ, Scinicariello F, Hilliard JK. Risk of venereal B virus (cercopithecine herpesvirus 1) transmission in rhesus monkeys using molecular epidemiology. J Infect Dis. 1995 May. 171(5):1139-43. [Medline].